Advertisement
For veterans with diabetes and concomitant chronic kidney disease (CKD)

Care for Chronic Kidney Disease Varies Across VA Facilities

0
Findings observed for veterans with diabetes and concomitant chronic kidney disease
The incidence of amphetamine and opioid use has increased among pregnant women

Increase Seen in Amphetamine, Opioid Use in Pregnant Women

0
Increase in amphetamine-, opioid-related deliveries disproportionate between rural vs. urban counties
All lots of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide combination blood pressure tablets have been recalled by Teva Pharmaceuticals due to higher-than-acceptable levels of a chemical that may cause cancer.

Teva Recalls Two Blood Pressure Medications

0
Tablets tainted with N-nitrosodiethylamine, a suspected human carcinogen
Certain sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

0
Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
Most proposed bills in state legislatures from 2011 to 2017 sought to expand access to immunization exemptions

Most Bills Enacted Into Law Limit Vaccine Exemptions

0
However, more than half of proposed bills sought to expand access to immunization exemptions
Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome.

FDA Approves Firdapse for Rare Autoimmune Disorder

0
First agency-sanctioned treatment for adults with Lambert-Eaton myasthenic syndrome
Xospata (gilteritinib) tablets were approved today by the U.S. Food and Drug Administration for treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with an FLT3 mutation

FDA Approves Treatment for AML Patients With Gene Mutation

0
Expanded approval also granted to mutation assay used to detect FLT3 mutation in AML patients
For patients with hereditary angioedema type I or II

Lanadelumab Reduces Attack Rate in Hereditary Angioedema

0
Significant reduction in attack rate compared with placebo seen for three dose regimens of lanadelumab
In addition to many other health risks

FDA: Kratom Products Have High Levels of Heavy Metals

0
New concern added to list of the agency's warnings about the herbal supplement
Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan

FDA Approves First Biosimilar to Non-Hodgkin’s Lymphoma Drug

0
Truxima approved to treat adults with CD20-positive, B-cell non-Hodgkin's lymphoma